ArticleMolecular biology reports2026
In vitro evaluation of the Anticarcinogenic effects of zerumbone in the SK-UT-1 human uterine Leiomyosarcoma cell line.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundUterine leiomyosarcoma (uLMS) is the most common subtype of uterine sarcomas characterized by high recurrence, metastasis rates, and limited responsiveness to conventional therapies. Zerumbone has been proven that have chemotherapeutic effects on cancer by modulating many molecular targets. The present study aimed to evaluate, for the first time, the antiproliferative potential of zerumbone against SK-UT-1 human uterine leiomyosarcoma cells. METHODS AND
resultsCell viability was assessed by CCK-8 assay. To evaluate the effect of zerumbone on apoptosis and cell cycle progression in SK-UT-1 cells, Annexin V and PI staining apoptosis assay and the PI staining assay were performed, respectively. To determine the cell cycle regulation and apoptosis-related gene expression changes, total RNA was isolated from SK-UT-1 cells treated with zerumbone and untreated control cells. The cDNAs were synthesized by Reverse transcription assay, and gene expressions were analysed using qRT-PCR. Zerumbone significantly decreased the viability of SK-UT-1 cells in a dose- and time-dependent manner. Flow cytometry analysis revealed that zerumbone induced G0/G1-phase arrest, followed by apoptosis and suppressed cell proliferation in SK-UT-1 cells.
conclusionThus, our data indicate that zerumbone may represent a promising candidate for further investigation as potential therapeutic agents for uLMS, including its possible use in combination therapy.
Indexed as
Identifiers
42776289What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.